Cardiac Arrhythmias in Patients with Exacerbation of COPD
Supraventricular and ventricular arrhythmias are common among patients with chronic obstructive pulmonary disease (COPD). Multiple factors can contribute to the development of arrhythmias in patients with exacerbation of the disease, including: respiratory or heart failure, hypertension, coronary disease and also medications. In the present study we seek to determine the prevalence of cardiac arrhythmias and risk factors among patients with exacerbation of COPD. The study was a retrospective evaluation of 2753 24-h Holter recordings of patients hospitalized in 2004–2016. Exacerbation of COPD was diagnosed in 152 patients and the prevalence of arrhythmias in this group of patients was 97%. The commonest arrhythmia was ventricular premature beats (VPB) – 88.8%, followed by supraventricular premature beats (SPB) – 56.5%. Permanent atrial fibrillation accounted for 30.3% and paroxysmal atrial fibrillation (PAF) for 12.5%. Supraventricular tachycardia (SVT) was noted in 34.2% patients and ventricular tachycardia in 25.6%. Respiratory failure increased the risk of SPB, while heart failure increased the risk of VPB. Treatment with theophylline was associated with a higher proportion of PAF and SVT. In conclusion, COPD exacerbation is associated with a high prevalence of cardiac arrhythmias. COPD treatment and comorbidities increase the risk of arrhythmias.
KeywordsAdverse effects Arrhythmias Comorbidities COPD exacerbation ECG monitoring Risk factors
The authors declare no conflict of interest in relation to this article.
- Baranowski R, Bieganowska K, Cygankiewicz I (2013) Guidelines on the implementation of long-term ECG recording. Kardiol Pol 71(Suppl. 9):225–242. Article in PolishGoogle Scholar
- Boyle M, Wong J (2006) Prescribing oxygen therapy. An audit of oxygen prescribing practices on medical wards at North Shore Hospital, Auckland, New Zealand. N Z Med J 119:2080Google Scholar
- Connors AF, Dawson NV, Thomas C, Harrell FE Jr, Desbiens N, Fulkerson WJ, Kussin P, Bellamy P, Goldman L, Knaus WA (1996) Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to understand prognoses and preferences for outcomes and risks of treatments). Am J Respir Crit Care Med 154:959–967CrossRefPubMedGoogle Scholar
- GOLD (2016) Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease. https://www.goldcopd.org. Accessed 17 Oct 2016
- Khan S, Jones S, Preston CL (2014) Theophylline interactions. Pharm J 293:7818Google Scholar
- Lahousse L, De Nocker P, Hofman A, Stricker B, Brusselle G, Verhamme K (2016) Potential use of β-blockers to reduce COPD exacerbations. Eur Respir J 48(Suppl 60). https://erj.ersjournals.com/content/48/suppl_60/OA1502.full. Accessed 10 Nov 2016
- Rudge J, Odedra S, Harrison D (2014) A new oxygen prescription produces real improvements in therapeutic oxygen use. BMJ Qual Improv Report 3(1). doi: 10.1136/bmjquality.u204031.w1815
- Shibata Y, Watanabe T, Osaka D, Abe S, Inoue S, Tokairin Y, Igarashi A, Yamauchi K, Kimura T, Kishi H, Aida Y, Nunomiya K, Nemoto T, Sato M, Konta T, Kawata S, Kato T, Kayama T, Kubota I (2011) Impairment of pulmonary function is an independent risk factor for atrial fibrillation: the Takahata study. Int J Med Sci 8:514–522CrossRefPubMedPubMedCentralGoogle Scholar
- Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R (2013b) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187:347–365CrossRefPubMedGoogle Scholar